Small Cell Lung Cancer Market Projected to Expand by 2034 | Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, and Amgen Expected to Drive Growth

The Small Cell Lung Cancer (SCLC) market is anticipated to grow due to factors such as increasing disease prevalence, rising investments in research and development, and the introduction of new therapies over the forecast period from 2020 to 2034.

The market report provides a comprehensive overview of SCLC, including market size and share, epidemiology, emerging treatment options, key drivers and challenges, ongoing clinical trials, notable collaborations, and therapy adoption by leading companies actively contributing to market growth.

Some of the key highlights from the Small Cell Lung Cancer Market Insights Report:

According to DelveInsight, the Small Cell Lung Cancer (SCLC) market is expected to grow at a notable CAGR from 2024 to 2034. Several leading pharmaceutical companies, including Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, and Amgen, are actively developing innovative therapies to improve the treatment landscape for SCLC.
In December 2024, Xcovery Holdings, Inc. announced that the U.S. FDA approved ensartinib (Ensacove) for treating patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), offering a significant new first-line therapy option. In September 2024, AbbVie submitted a biologics license application (BLA) seeking accelerated FDA approval for telisotuzumab vedotin (Teliso-V) to treat previously treated nonsquamous NSCLC with c-Met protein overexpression.
The SCLC market growth is driven by the introduction of new therapies and the rising incidence of lung cancer, which affects over 200,000 people annually in the U.S. and an estimated 2.3 million globally. SCLC represents 10% to 15% of all lung cancer cases. The 5-year relative survival rate in the U.S. is 8% for women and 6% for men.
Current treatment options include IMFINZI (durvalumab) for extensive-stage SCLC and ZEPZELCA (lurbinectedin) for metastatic disease. Approximately 25% of patients with limited-stage SCLC can achieve a cure with timely chemotherapy and radiation therapy. The traditional first-line regimen is platinum-etoposide, with topotecan as a second-line therapy, though its response rate is limited (~20%) and survival benefit is modest compared to best supportive care.
SCLC treatment options and outcomes remain limited compared to non-small cell lung cancer (NSCLC), which has benefited from targeted therapies and immunotherapy advancements. While immunotherapy shows promise for SCLC, challenges persist regarding efficacy and toxicity, emphasizing the need for additional treatment options across disease subtypes. Companies such as Ipsen Biopharmaceuticals (Onivyde), Bristol-Myers Squibb (BMS-986012), Xcovery Holding Company (Vorolanib), EpicentRx (RRx-001), and Amgen (AMG 757) are progressing their lead candidates through clinical development.
In 2023, the U.S. reported approximately 238,340 new lung cancer cases (117,550 men and 120,790 women), encompassing both SCLC and NSCLC. SCLC accounts for 10-15% of cases, with NSCLC representing 80-85%. SCLC is slightly more common in women (14%) than men (13%), and diagnosis is most likely between ages 75-79. In the UK, SCLC makes up 15-20% of lung cancer diagnoses, primarily caused by smoking, and is characterized by early metastasis.

Strategise your business goals by understanding market dynamics @ Small Cell Lung Cancer Market Landscape @ https://www.delveinsight.com/report-store/small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Small Cell Lung Cancer Overview

Small Cell Lung Cancer (SCLC) is an aggressive type of lung cancer marked by the rapid and uncontrolled growth of lung cells, often resulting in tumor formation and early metastasis to other organs. Smoking is the leading risk factor, with nearly all cases occurring in current or former smokers. Early stages of SCLC often show no noticeable symptoms, and when symptoms do arise, they can differ significantly between patients.

Diagnosis typically involves imaging tests such as CT, PET, or MRI scans to detect lung abnormalities. In some cases, a mucus sample may be analyzed for the presence of cancer cells. If cancer is suspected, a biopsy-performed using a needle or minor surgical procedure-is conducted to obtain lung tissue for examination. Bronchoscopy is another common method, allowing direct visualization of the lungs and collection of tissue samples for testing.

Do you know the treatment paradigms for different countries? Download our Small Cell Lung Cancer Market Sample Report @ https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Small Cell Lung Cancer Epidemiology Segmentation

DelveInsight's Small Cell Lung Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Small Cell Lung Cancer historical patient pools and forecasted Small Cell Lung Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Small Cell Lung Cancer Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Small Cell Lung Cancer Prevalence
Age-Specific Small Cell Lung Cancer Prevalence
Gender-Specific Small Cell Lung Cancer Prevalence
Diagnosed and Treatable Cases of Small Cell Lung Cancer

Visit for more @ Small Cell Lung Cancer Epidemiological Insights @ https://www.delveinsight.com/report-store/small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Small Cell Lung Cancer Treatment Market

Over the past three decades, improvements in survival rates for Small Cell Lung Cancer (SCLC) patients have been limited, primarily due to the disease's aggressive nature, early metastasis, and chemotherapy resistance. Treatment strategies depend on cancer stage, patient health, and individual preferences, and may include surgery, chemotherapy, radiation, or immunotherapy. Standard chemotherapy regimens often combine Etoposide or Irinotecan with a platinum-based drug such as Cisplatin or Carboplatin. Patients with limited-stage SCLC typically receive combined chemotherapy and radiation, whereas extensive-stage disease is usually treated with chemotherapy, sometimes in combination with immunotherapy.

Recent advancements have introduced immune checkpoint inhibitors-including nivolumab, pembrolizumab, atezolizumab, and durvalumab-as part of first-line therapy. Lurbinectedin is approved for second-line treatment, and trilaciclib helps mitigate chemotherapy-induced myelosuppression. However, in 2021, FDA approvals for nivolumab and pembrolizumab in later-stage SCLC were withdrawn, though they are still used in combination with other therapies.

Ongoing research aims to develop new treatments, with hopes that biomarker-driven approaches may enhance outcomes similarly to non-Small Cell Lung Cancer (NSCLC). Companies such as Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, and Amgen are actively progressing novel therapies through clinical trials.
Small Cell Lung Cancer Marketed Drugs
ZEPZELCA (lurbinectedin): PharmaMar and Jazz Pharmaceuticals
IMFINZI (durvalumab): AstraZeneca
Small Cell Lung Cancer Emerging Drugs
RRx-001: EpicentRx
Small Cell Lung Cancer Key Companies
Bristol-Myers Squibb
Merck
AstraZeneca
PharmaMar
EpicentRx
And others
For more information, visit Small Cell Lung Cancer Market Analysis, Patient Pool, and Emerging Therapies @ https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kritikapr

Scope of the Small Cell Lung Cancer Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Small Cell Lung Cancer, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Small Cell Lung Cancer epidemiology in the 7MM
Small Cell Lung Cancer marketed and emerging therapies
Small Cell Lung Cancer companies
Small Cell Lung Cancer market drivers and barriers

Table of Contents:

1 Small Cell Lung Cancer Market Key Comprehensive Insights
2 Small Cell Lung Cancer Market Report Introduction
3 Competitive Intelligence Analysis for Small Cell Lung Cancer
4 Small Cell Lung Cancer Market Analysis Overview at a Glance
5 Executive Summary of Small Cell Lung Cancer
6 Small Cell Lung Cancer Epidemiology and Market Methodology
7 Small Cell Lung Cancer Epidemiology and Patient Population
8 Small Cell Lung Cancer Patient Journey
9 Small Cell Lung Cancer Treatment Algorithm, Small Cell Lung Cancer Current Treatment, and Medical Practices
10 Key Endpoints in Small Cell Lung Cancer Clinical Trials
11 Small Cell Lung Cancer Marketed Therapies
12 Small Cell Lung Cancer Emerging Therapies
13 Small Cell Lung Cancer: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Small Cell Lung Cancer
16 Small Cell Lung Cancer Market Key Opinion Leaders Reviews
18 Small Cell Lung Cancer Market Drivers
19 Small Cell Lung Cancer Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight

Related Reports:

Small Cell Lung Cancer Epidemiology 2034

DelveInsight's "Small Cell Lung Cancer - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Small Cell Lung Cancer Pipeline 2024

"Small Cell Lung Cancer Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Small Cell Lung Cancer market. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Small Cell Lung Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.